Venetoclax
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Venetoclax
- Venetoclax: From Acute Lymphoblastic Leukemia and Richter Syndrome to CLL/SLL with IGHV Somatic Hypermutation
Venetoclax: From Acute Lymphoblastic Leukemia and Richter Syndrome to CLL/SLL with IGHV Somatic Hypermutation
One-Sentence Summary
Venetoclax is an oral BCL-2 inhibitor. The knowledge graph used for prediction lists acute lymphoblastic leukemia and Richter syndrome as its original indications. The TxGNN model predicts it may be effective for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with immunoglobulin heavy chain variable-region gene somatic hypermutation. For this specific subtype there are currently 0 clinical trials and 0 publications supporting the prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute lymphoblastic/lymphocytic leukemia; Richter syndrome (from the prediction knowledge graph; no indication text is recorded on the Singapore licences) |
| Predicted New Indication | CLL/SLL with immunoglobulin heavy chain variable-region gene somatic hypermutation (IGHV-mutated CLL/SLL) |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 (model prediction only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Venetoclax is nonetheless a well-known selective BCL-2 inhibitor. BCL-2 is an anti-apoptotic protein that many B-cell malignancies depend on, and blocking it restores programmed cell death in the cancer cells. CLL/SLL cells characteristically overexpress BCL-2, so the mechanism is biologically plausible for this subtype.
This prediction is not a true repurposing case. Venetoclax is already established in CLL generally, and IGHV-mutated CLL/SLL is a molecular subtype of that disease. The model's high score probably reflects this close relationship to indications venetoclax already has. It is not evidence of a newly discovered use.
The data compiled for this report also contain no subtype-specific trials or publications. The plausibility is therefore mechanistic and by analogy to CLL as a whole, not demonstrated for the IGHV-mutated subtype.
Clinical Trial Evidence
Currently no related clinical trials registered for this specific indication.
Literature Evidence
Currently no related literature available for this specific indication.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN15267P | VENCLEXTA film-coated tablet 100 mg | Tablet, film coated |
| SIN15266P | VENCLEXTA film-coated tablet 50 mg | Tablet, film coated |
| SIN15265P | VENCLEXTA film-coated tablet 10 mg | Tablet, film coated |
All three licences are valid single-ingredient products (oral route) held by AbbVie. Approved indication text is not recorded for these licences.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BCL-2 inhibitor), not a conventional cytotoxic agent |
| Myelosuppression Risk | Medium. Published reviews describe tumour lysis syndrome and myelosuppression as the most common toxicities, especially in combination regimens. |
| Emetogenicity Classification | Low (general class expectation; please confirm against the package insert) |
| Monitoring Items | CBC with differential, tumour lysis syndrome labs (electrolytes, uric acid, creatinine), liver and renal function |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 potential interactions, and 20 are detailed here.
- Major: aprepitant, dexamethasone, clarithromycin, eliglustat, rolapitant, fidaxomicin, cobicistat, deferiprone, samarium (153Sm) lexidronam.
- Moderate: for example alvimopan, loperamide, cimetidine, miconazole, clotrimazole, rifaximin, deferasirox.
- Minor: naloxegol.
- Venetoclax is a CYP3A substrate. A published study of the strong CYP3A inhibitor posaconazole (PMID 28161120) showed that dose adjustment is needed when they are co-administered.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is mechanistically plausible but has no trials or publications specific to IGHV-mutated CLL/SLL. It is also a subtype of an already established CLL use rather than a new repurposing opportunity. Within the same prediction list, acute myeloid leukemia has far stronger evidence (L1) and is the more productive direction to evaluate.
To proceed, the following is needed:
- Subtype-specific clinical data (trials or publications) for IGHV-mutated CLL/SLL
- Confirmation of the Singapore-approved indications and the full warnings and contraindications from the HSA package insert
- Detailed mechanism-of-action data
- A drug-interaction management plan, particularly for CYP3A inhibitors, and a tumour lysis syndrome and myelosuppression monitoring plan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.